Ignite Creation Date:
2025-12-24 @ 9:59 PM
Ignite Modification Date:
2026-02-25 @ 5:52 PM
Study NCT ID:
NCT02994732
Status:
COMPLETED
Last Update Posted:
2019-06-17
First Post:
2016-11-14
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000618314', 'term': 'ulixertinib'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'Dknoerzer@biomed-valley.com', 'phone': '636-887-6429', 'title': 'Associate Director of Translational Sciences', 'organization': 'Biomed Valley Discoveries'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': '27 days', 'description': 'Adverse event definitions; assignment of severity, causality, action taken, and outcome; and procedures for reporting serious AEs (SAEs) are detailed in Appendix C of the protocol. None of the definitions differ from the clinicaltrials.gov definitions.', 'eventGroups': [{'id': 'EG000', 'title': 'Single Arm Study', 'description': 'Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.', 'otherNumAtRisk': 6, 'deathsNumAtRisk': 6, 'otherNumAffected': 2, 'seriousNumAtRisk': 6, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Fatigue', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 6, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) Tmax', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental [14C] -BVD-523 600mg Single Dose', 'description': 'Subjects will receive a single oral 600-mg (4 ×150-mg capsules) dose of BVD-523 containing approximately 200 µCi of \\[14C\\] labeled BVD-523 following a 2-hour fast that follows breakfast. Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.57', 'spread': '3.0', 'groupId': 'OG000'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Collected over 5 days', 'description': 'Time to peak concentration (Tmax), PK blood samples were taken at the following time points 0 (predose), 30 min, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours post dose.', 'unitOfMeasure': 'hr', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled subjects'}, {'type': 'PRIMARY', 'title': 'Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) Cmax', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Single Arm Study', 'description': 'Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'classes': [{'categories': [{'measurements': [{'value': '1110', 'spread': '619', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Collected over 5 days', 'description': 'peak (maximum) concentration', 'unitOfMeasure': 'ng/ml', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All 6 subjects enrolled'}, {'type': 'PRIMARY', 'title': 'Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) t1/2', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental [14C] -BVD-523 600mg Single Dose', 'description': 'Subjects will receive a single oral 600-mg (4 ×150-mg capsules) dose of BVD-523 containing approximately 200 µCi of \\[14C\\] labeled BVD-523 following a 2-hour fast that follows breakfast. Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.75', 'spread': '3.57', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Collected over 15 days', 'description': 'Elimination half-life', 'unitOfMeasure': 'hr', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled subjects'}, {'type': 'PRIMARY', 'title': 'Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) AUC', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental [14C] -BVD-523 600mg Single Dose', 'description': 'Subjects will receive a single oral 600-mg (4 ×150-mg capsules) dose of BVD-523 containing approximately 200 µCi of \\[14C\\] labeled BVD-523 following a 2-hour fast that follows breakfast. Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'classes': [{'categories': [{'measurements': [{'value': '8480', 'spread': '3600', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Collected over 15 dyas', 'description': 'Area under Curve (AUC), 0-24 hr', 'unitOfMeasure': 'hr*ng/ml', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled subjects'}, {'type': 'PRIMARY', 'title': 'Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) CL/F', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental [14C] -BVD-523 600mg Single Dose', 'description': 'Subjects will receive a single oral 600-mg (4 ×150-mg capsules) dose of BVD-523 containing approximately 200 µCi of \\[14C\\] labeled BVD-523 following a 2-hour fast that follows breakfast. Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'classes': [{'categories': [{'measurements': [{'value': '73', 'spread': '35.1', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Collected over 15 days', 'description': 'Oral Clearance (CL/F)', 'unitOfMeasure': 'L/hr', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled subjects'}, {'type': 'PRIMARY', 'title': 'Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) V/F', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental [14C] -BVD-523 600mg Single Dose', 'description': 'Subjects will receive a single oral 600-mg (4 ×150-mg capsules) dose of BVD-523 containing approximately 200 µCi of \\[14C\\] labeled BVD-523 following a 2-hour fast that follows breakfast. Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'classes': [{'categories': [{'measurements': [{'value': '899', 'spread': '463', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Collected over 15 days', 'description': 'Apparent volume of distribution (V/F)', 'unitOfMeasure': 'L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled subjects'}, {'type': 'PRIMARY', 'title': 'Excretion Rate of 14C-labeled BVD-523(Radioactivity in Feces)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental [14C] -BVD-523 600mg Single Dose', 'description': 'Subjects will receive a single oral 600-mg (4 ×150-mg capsules) dose of BVD-523 containing approximately 200 µCi of \\[14C\\] labeled BVD-523 following a 2-hour fast that follows breakfast. Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'classes': [{'categories': [{'measurements': [{'value': '82', 'spread': '4.72', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Collected over 15 days', 'description': 'Percent of dose excreted in feces', 'unitOfMeasure': '%of radioactive dose of [14C-BVD523', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled subjects'}, {'type': 'PRIMARY', 'title': 'Excretion Rate of 14C-labeled BVD-523(Radioactivity in Urine)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental [14C] -BVD-523 600mg Single Dose', 'description': 'Subjects will receive a single oral 600-mg (4 ×150-mg capsules) dose of BVD-523 containing approximately 200 µCi of \\[14C\\] labeled BVD-523 following a 2-hour fast that follows breakfast. Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'classes': [{'categories': [{'measurements': [{'value': '14.8', 'spread': '4.79', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Collected over 15 days', 'description': 'Percent of dose excreted in urine', 'unitOfMeasure': '% of radioactive dose of [14C-BVD523', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled subjects'}, {'type': 'PRIMARY', 'title': 'Cumulative Whole Blood: Plasma Ratio Calculated for AUC0-12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental [14C] -BVD-523 600mg Single Dose', 'description': 'Subjects will receive a single oral 600-mg (4 ×150-mg capsules) dose of BVD-523 containing approximately 200 µCi of \\[14C\\] labeled BVD-523 following a 2-hour fast that follows breakfast. Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.464', 'spread': '0.0354', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Collected in 12 hrs', 'description': 'AUC from time zero to the 12 hr time point with concentration above the lower limit of quantitation', 'unitOfMeasure': 'hr*ng/ml', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled subjects'}, {'type': 'PRIMARY', 'title': 'Cumulative Whole Blood: Plasma Ratio Calculated for AUC 0-24', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Experimental [14C] -BVD-523 600mg Single Dose', 'description': 'Subjects will receive a single oral 600-mg (4 ×150-mg capsules) dose of BVD-523 containing approximately 200 µCi of \\[14C\\] labeled BVD-523 following a 2-hour fast that follows breakfast. Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.409', 'spread': '0.0297', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Collected in 24 hrs', 'description': 'AUC from time zero to 24 hrs', 'unitOfMeasure': 'hr*ng/ml', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled subjects'}, {'type': 'SECONDARY', 'title': 'Treatment-related Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Single Arm Study', 'description': 'Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'classes': [{'categories': [{'measurements': [{'value': '2', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '27 days', 'description': 'Any treatment-emergent adverse events related or likely related to study treatment', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled subjects'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Experimental [14C] - BVD-523 600mg Single Dose', 'description': 'Subjects received a single oral 600-mg (4 ×150-mg capsules) dose of BVD-523 containing approximately 200 µCi of \\[14C\\] labeled BVD-523 following a 2-hour fast that followed breakfast. Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'comment': 'All subjects entered clinic on January 11, 2017', 'groupId': 'FG000', 'numSubjects': '6'}]}, {'type': 'COMPLETED', 'achievements': [{'comment': 'All subjects were discharged from the clinic by Jan 24, 2017', 'groupId': 'FG000', 'numSubjects': '6'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Single Arm Study', 'description': 'Six subjects were enrolled in, dosed, and completed study. All six subjects were male, 4 subjects were white and 2 subjects were black or African American.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '39.0', 'spread': '16.6', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '6', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Black or African American', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}, {'title': 'White', 'measurements': [{'value': '4', 'groupId': 'BG000'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '6', 'groupId': 'BG000'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}, {'title': 'BMI', 'classes': [{'categories': [{'measurements': [{'value': '24.9', 'spread': '2.38', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'kg/m^2', 'dispersionType': 'STANDARD_DEVIATION'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2016-12-07', 'size': 469532, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2018-04-24T16:15', 'hasProtocol': True}, {'date': '2017-03-29', 'size': 508574, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2018-04-24T16:55', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'OTHER', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 6}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2017-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-03', 'completionDateStruct': {'date': '2017-05-15', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-03-14', 'studyFirstSubmitDate': '2016-11-14', 'resultsFirstSubmitDate': '2018-04-24', 'studyFirstSubmitQcDate': '2016-12-13', 'lastUpdatePostDateStruct': {'date': '2019-06-17', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2019-03-14', 'studyFirstPostDateStruct': {'date': '2016-12-16', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2019-06-17', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-02', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) Tmax', 'timeFrame': 'Collected over 5 days', 'description': 'Time to peak concentration (Tmax), PK blood samples were taken at the following time points 0 (predose), 30 min, 1, 2, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours post dose.'}, {'measure': 'Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) Cmax', 'timeFrame': 'Collected over 5 days', 'description': 'peak (maximum) concentration'}, {'measure': 'Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) t1/2', 'timeFrame': 'Collected over 15 days', 'description': 'Elimination half-life'}, {'measure': 'Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) AUC', 'timeFrame': 'Collected over 15 dyas', 'description': 'Area under Curve (AUC), 0-24 hr'}, {'measure': 'Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) CL/F', 'timeFrame': 'Collected over 15 days', 'description': 'Oral Clearance (CL/F)'}, {'measure': 'Pharmacokinetics of 14C-labeled BVD-523(Radioactivity in Whole Blood and Plasma) V/F', 'timeFrame': 'Collected over 15 days', 'description': 'Apparent volume of distribution (V/F)'}, {'measure': 'Excretion Rate of 14C-labeled BVD-523(Radioactivity in Feces)', 'timeFrame': 'Collected over 15 days', 'description': 'Percent of dose excreted in feces'}, {'measure': 'Excretion Rate of 14C-labeled BVD-523(Radioactivity in Urine)', 'timeFrame': 'Collected over 15 days', 'description': 'Percent of dose excreted in urine'}, {'measure': 'Cumulative Whole Blood: Plasma Ratio Calculated for AUC0-12', 'timeFrame': 'Collected in 12 hrs', 'description': 'AUC from time zero to the 12 hr time point with concentration above the lower limit of quantitation'}, {'measure': 'Cumulative Whole Blood: Plasma Ratio Calculated for AUC 0-24', 'timeFrame': 'Collected in 24 hrs', 'description': 'AUC from time zero to 24 hrs'}], 'secondaryOutcomes': [{'measure': 'Treatment-related Adverse Events', 'timeFrame': '27 days', 'description': 'Any treatment-emergent adverse events related or likely related to study treatment'}]}, 'conditionsModule': {'conditions': ['Healthy']}, 'descriptionModule': {'briefSummary': 'The primary objective of this study is to characterize the metabolic disposition, pharmacokinetics (PK), and routes of elimination of \\[14C\\]-labeled BVD-523 after administration of a single, oral dose to healthy male subjects.\n\nThe secondary objective of this study is to evaluate the safety and tolerability of a single oral dose of \\[14C\\]-labeled BVD-523 in healthy male subjects.', 'detailedDescription': 'This study will be an open-label, absorption, metabolism, and excretion study of \\[14C\\]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Males, between 18 and 65 years of age, inclusive, at Screening\n* Have a body mass index range of 18.5 to 32.0 kg/m2, inclusive, at Screening\n* In good health, determined by no clinically significant findings from medical history, 12-lead ECG, and vital signs measurements at Screening or Check-in and PE findings at Check-in as determined by the Investigator (or designee)\n* Clinical laboratory evaluations (including clinical chemistry panel \\[fasted at least 8 hours\\], hematology/complete blood count \\[CBC\\], and urinalysis \\[UA\\] within the reference range for the test laboratory at Screening and Check-in, unless deemed not clinically significant by the Investigator (or designee)\n* Negative test for selected drugs of abuse and cotinine at Screening (does not include alcohol) and at Check-in (does include alcohol)\n* Negative hepatitis panel (including hepatitis B surface antigen and hepatitis C virus antibody) and negative human immunodeficiency virus (HIV) antibody screens at Screening\n* Males will be surgically sterile for at least 90 days (confirmed by documented azoospermia) or, when sexually-active with female partners of child-bearing potential, will agree to use contraception as detailed in Section 6.3.3 from Check-in until 90 days following Discharge\n* Males must be willing to refrain from sperm donation from Check-in to 90 days from day of dosing\n* Able to comprehend and willing to sign an ICF\n* A minimum of 1 bowel movement per day.\n\nExclusion Criteria:\n\n* Significant history or clinical manifestation of any metabolic, allergic, infectious, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder (as determined by the Investigator \\[or designee\\]) prior to Check-in\n* History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) prior to Check-in\n* History of stomach or intestinal surgery or resection that could alter absorption or excretion of orally administered drugs prior to Check-in except appendectomy, and hernia repair will be allowed if it was not associated with;\n* History of Gilbert's Syndrome\n* History or presence of an abnormal ECG that, in the Investigator's (or designee's) opinion, is clinically significant\n* History of alcoholism or drug addiction within 1 year prior to Check-in\n* History of nicotine use within 6 months prior to Check-in or positive cotinine at Screening or Check-in\n* Participation in more than 1 other radiolabeled investigational study drug trial within 12 months prior to Check-in. The previous radiolabeled study drug must have been received more than 6 months prior to Check-in for this study and the total exposure from this study and the previous study will be within the recommended levels considered safe, per United States (US) Title 21 Code of Federal Regulations (CFR) 361.1 (eg, less than 3,000 mrem whole body annual exposure)\n* Exposure to significant radiation (eg, serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months prior to Check-in\n* Use of any drugs or substances known to be strong inhibitors or strong inducers of CYP3A enzyme within 30 days prior to study drug administration, unless otherwise stated, and throughout the study\n* Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within 5 half-lives (if known) or 30 days prior to Check-in, whichever is longer\n* Use of any prescription medications/products within 14 days prior to Check-in, unless deemed acceptable by the Investigator (or designee)\n* Use of any over-the-counter, nonprescription preparations (including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations) within 7 days prior to Check-in, unless deemed acceptable by the Investigator (or designee)\n* Poor peripheral venous access prior to Check-in\n* Donation of whole blood from 56 days prior to Screening through Discharge, inclusive, or of plasma from 30 days prior to Screening through Discharge, inclusive\n* Receipt of blood products within 2 months prior to Check-in\n* Any acute or chronic condition that, in the opinion of the Investigator (or designee), would limit the subject's ability to complete or participate in this clinical study\n* Any other unspecified reason that, in the opinion of the Investigator (or designee) or Sponsor, make the subject unsuitable for enrollment"}, 'identificationModule': {'nctId': 'NCT02994732', 'briefTitle': 'Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers', 'organization': {'class': 'INDUSTRY', 'fullName': 'BioMed Valley Discoveries, Inc'}, 'officialTitle': 'A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BVD-523 Following Single Oral Dose Administration in Healthy Male Subjects', 'orgStudyIdInfo': {'id': '523HV001'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': '[14C]-BVD-523 600mg single dose', 'description': 'Open-label, nonrandomized, absorption, metabolism, and excretion study of \\[14C\\]-BVD-523 administered as a 600 mg (approximately 200 µCi) oral dose to 6 healthy male subjects following at least an 8-hour fast from food (not including water).', 'interventionNames': ['Drug: [14C]-BVD-523']}], 'interventions': [{'name': '[14C]-BVD-523', 'type': 'DRUG', 'otherNames': ['Ulixertinib'], 'description': '\\[14C\\]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.', 'armGroupLabels': ['[14C]-BVD-523 600mg single dose']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Irene Mirkin, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Covance'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'BioMed Valley Discoveries, Inc', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}